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Background: Most offered pancreases are not transplanted. This study investigates the factors that inform and
influence the transplant surgeon’s decision to select an offered pancreas.
Methods: Semi-standardized interviews were conducted with 14 highly qualified transplant surgeons from all 14
German transplant centers performing > 5 pancreas transplantations per year. The interviews focused on medical
and non-medical criteria on which the individual accept/refuse decision depends. Interviews were recorded,
transcribed and underwent content analysis.
Results: The interviewees agreed upon certain main selection criteria, e.g. donor age, lab results, ICU stay. However,
there was no consistency in judging these parameters, and clear cut-offs did not exist. The pancreas macroscopy is
a pivotal factor, as well as knowing (and trusting) the donor surgeon. 3/14 surgeons reported that they had
occasionally refused a pancreas because of staff shortage. Some interviewees followed a restrictive acceptance
policy, whereas others preferred to accept almost any pancreas and inspect it personally before deciding.
Conclusion: The assessment of medical donor characteristics is highly inconsistent. Both very cautious as well as
very permissive acceptance policies may render the allocation process less efficient. A more standardized policy
should be discussed. Finally, better training for donor surgeons seems advisable, in order to increase trust and thus
pancreas utilization.
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Whole organ pancreas-kidney transplantation has be-
come the standard treatment for type 1 diabetes mellitus
patients with renal failure [1-6]. However, not all patients
eligible for pancreas transplantation can benefit from this
therapeutic option, mainly because of the well-known
shortage of donor organs. The waiting time for receiving a
pancreas transplant has considerably increased in several
European countries over the last few years [7]. In addition,
the majority of pancreases that are offered for allocation
are not transplanted [7]. Data from Eurotransplant (ET),
an international foundation responsible for the allocation
of donor organs in Austria, Belgium, Croatia, Germany,* Correspondence: julika.loss@ukr.de
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reproduction in any medium, provided the orLuxembourg, the Netherlands and Slovenia, indicate that
71% of all offered pancreases are withdrawn or discarded.
The reasons for this pancreas under-utilization are not yet
well understood. Data from the UK indicate that the ma-
jority of organs are withdrawn from the allocation process
because they are repeatedly turned down from the con-
tacted transplant centers due to medical characteristics of
the donor [8]. In Germany, data from 2005–2009 show
that 43% of pancreases are withdrawn before recovery be-
cause of repeated refusals, and 20% are discarded at the
time of intended recovery, or after recovery, mainly due to
poor organ macroscopy [9].
When an organ is consented to be allocated for trans-
plantation, the physician or surgeon from the transplant
center with the patient ranked highest on the waiting list
is contacted by phone [10]. In parallel, a recovery team
in the region of the donor hospital is instructed to. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to use the organ is prerogative of the transplant surgeon
and/or physician responsible for the care of the recipient
[10]. Many of these offers are turned down on the phone;
data from German pancreas donors show that a pancreas
is offered to a median of three centers before it is placed
[9]; those pancreases withdrawn from the allocation
process had been offered to a median of eight patients in
five centers. This begs the questions as to which factors
may influence a transplant surgeon’s decision to accept or
refuse a pancreas offer. For example, it is not known
whether medical characteristics of the donor are judged in
a similar way by different transplant surgeons, and if so,
what the underlying reasons may be. Based on the data
from the allocation process in Germany, there is no
consistency in the decision-making process using single
donor characteristics (e.g. BMI, ICU stay, age) [9]. It has
also been speculated that administrative (e.g. staff short-
age) or strategic aspects (e.g. survival rates) may play a
role when refusing organ offers [10]. Whether these con-
siderations actually affect the decision-making process has
not been analyzed yet. Neither has it been studied whether
the decision is rather intuitive, or based upon sound evi-
dence or consensus as to the medical criteria of the donor.
The objective of this study was to analyze
(1) Which medical donor characteristics have an
impact on a transplant surgeon’s decision to accept
or refuse an organ offer;
(2) Whether there are differences in evaluating
medical donor characteristics between transplant
surgeons of different centers with regard to
acceptance of an offered pancreas;
(3) To what extent non-medical reasons, e.g. staff
shortage, may play a role in the accept/refuse
decision in pancreas transplantation.
Methods
Sample
In Germany, 163 pancreases from donors after brain death
were transplanted in the year 2010 [11] (transplantation
from donors after circulatory death is not allowed in
Germany). These pancreas transplants were performed in
24 centers; the three hospitals with the highest volume
transplanted 13, 14, and 16 pancreases per year, respect-
ively. 14 of the centers transplanted more than five pan-
creases per year [11]. In all of these 14 relative ‘high
volume’ centers, experienced transplant surgeons are on
call to decide upon the acceptance or refusal of whole
organ donor pancreases when offered by Eurotransplant.
In most centers, 2–3 surgeons are specialized in pancreas
transplantation.
Semi-structured, face-to-face interviews were conducted
with surgical consultants from all 14 ‘high volume’pancreas transplant centers between May and November
2011). The interview partners (n = 14) met the following
inclusion criteria:
– employment at a transplant center performing >5
pancreas transplantations per year (according to
2010 data)
– minimum of three years of experience in pancreatic
transplant surgery
– routine responsibility for decisions on accepting or
refusing offered donor pancreases
Purposive sampling was used to recruit the sample.
Two transplant surgeons from transplant centers with
less than five pancreas transplants per year were inter-
viewed first in order to pre-test the interview guide; they
provided comments on the questions (for the final inter-
view guide see Table 1). These interviews were not in-
cluded in the analysis. All participants agreed to being
interviewed and recorded. The transcript, analysis and
presentation of data did not enable identification of indi-
vidual participants or their respective centers.
Data collection
The interviews covered factors that influence the trans-
plant surgeon’s decision to accept or refuse a pancreas.
If donor-related medical factors such as age, BMI or
length of ICU stay were named by the interview partner,
it was asked whether certain limits would apply for these
variables, and what these limits were. If non-medical
criteria were not mentioned spontaneously, e.g. staff
shortage, these aspects were asked explicitly. One of the
authors (KPD) conducted all the interviews, each of
which was audio-taped and lasted for 20–70 minutes.
Analysis
Interview tapes were transcribed verbatim. The tran-
scripts were de-identified and continuously numbered
(Interview Partner = IP 01-IP 14), so none of the re-
searchers, except the interviewer, could link the answers
back to the interviewed transplant surgeon or the re-
spective transplant center. The transcripts were exam-
ined using thematic content analysis [12]. Key themes
that spanned specific questions and topics were identi-
fied, and were used to organize the material [13]. In the
course of the data analysis, the initial categories, distin-
guishing between medical and non-medical factors influ-
encing the decision, evolved into more sophisticated
coding structures and additional categories, including
e.g. concepts of trust, patient’s prognosis, and strategic
aspects. To enhance the validity of the findings, the
interview transcripts were read and coded independently
by two authors (KPD and JL); deviant cases and contra-
dictory data were analyzed with particular attention [14].
Table 1 Interview guide
Introductory questions • How long have you been working as a transplant surgeon in a responsible position?
• Are you currently performing pancreas recoveries as well?
• If a pancreas is offered to your center, what is the usual process?
Broad topic 1: Deciding about a
pancreas offer
• When deciding about a pancreas offer from Eurotransplant, what criteria guide your decision?
- If medical/social parameters that are interval variables (e.g. age, BMI, length of ICU stay, P-PASS1)
are mentioned: Do you apply certain cut-offs for this parameter?
• How relevant is the macroscopic evaluation performed by the recovery team?
• How important is it for you that the donor and recipient match well?
Broad topic 2: Non-medical refusal
reasons
• How might your decision be influenced if you are told that the organ has been previously refused
by other centers?
• Have you ever heard that pancreases have been refused due to capacity reasons or even witnessed
it personally?
• Could you imagine that under certain circumstances, a pancreas might be refused due to
infrastructure reasons in your clinic, e.g. due to staff shortage? Has that ever happened?
1P-PASS = pre-procurement pancreas allocation suitability score, combining nine donor parameters, e.g. age, body mass index, ICU stay, and (nor)adrenaline use.
The DRI (donor risk index), an alternative prognostic score for pancreas transplantation, is not commonly used in Germany and was therefore not included
explicitly in the interview guide.
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Results
The 14 transplant surgeons reported to be performing
transplant surgery in authoritative positions for 3–
15 years. All interview partners with the exception of
one reported to be routinely involved in donor surgery
of the pancreas as well, being a member of a regional re-
covery team. According to the interview partners, trans-
plant surgeons have the sole responsibility of the accept/
refuse decision for offered pancreases in 11 transplant
centers, whereas a joint decision between transplant sur-
geons and nephrologists is the usual procedure in three
transplant centers.
As illustrated schematically in Figure 1, we identified
seven main factors influencing the decision-making
process (the numbers in brackets refer to Figure 1 andMedical reasons
1. Medical 
history
2. Organ 
macroscopy
3. Trus
recov
team
Figure 1 Categories of criteria that play a role when deciding to acceto the subheadings of the following text): The decision
to accept or refuse an offered donor pancreas is mainly
based on medical criteria. The key factors of medical
criteria are the donor’s medical history (1), and, signifi-
cantly more important, the donor organ macroscopy
(2). The decision-making process is also influenced by
confidence in the recovery team’s expertise (3). Non-
medical aspects play a role in certain circumstances,
mainly in terms of staff shortage (4) or prior decisions
of other centers (5). The decision is also influenced by
the comparatively benign prognosis of patients waiting for
a pancreas transplant (6). Finally, the decision-making
process can also be guided by strategic considerations, e.g.
regarding competition with other centers, or risk manage-
ment (7).
1. Donor medical historyNo
t in 
ery
pt/rejAll interview partners mentioned at least 3–6 donor
characteristics that are considered decisive for
evaluating a pancreas offer. Some of thesen-medical reasons
5. Decisions
of other
centers
4. Local
capacity
ect a pancreas.
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interview partner: age, length of ICU stay, cause of
death, lab results, and co-morbidities. Other
characteristics, such as BMI, history of alcohol
abuse, or administration of blood transfusions were
named less frequently. When asked about
resuscitation of the donor, the majority of interview
partners denied this criterion to be of importance.
While there was a broad consensus on the donor
characteristics that are relevant to evaluate a pancreas
offer, the cut-offs used for some of these characteristics
varied substantially between interview partners.
Donor age. Donor age plays a prominent role for the
evaluation of the pancreas. The upper age limit
which was considered acceptable ranged from 40 to
55 years of age. The majority of interviewed
surgeons pointed out that the donor age needed to
be judged in relation to other donor characteristics:
the more risk factors were present, the less tolerable
is an age above 45 or 50 years.
With a 50-year-old, you need to check what other
factors there might be…How is his/her glucose level?
Does co-morbidity play a role? Does the offered organ
appear to be from a biologically younger donor? (IP11).
Two surgeons, however, reported to have fix cut-offs
for donor age.We have relatively strict guidelines… It starts already
with age. As a rule, we do not accept organs that are
more than 40 years old. (IP 06)Length of ICU stay. Most interview partners
explained that they appraised the length of ICU stay
in relation to other donor characteristics; however,
there was a wide range of rough cut-offs mentioned
(from 5 days to 2–3 weeks up to 20–30 days).
[The length of ICU stay] should not exceed a week. If
it’s two and half to three weeks, I would be skeptical
about the organ. (IP 10)
[I don’t draw] a line there. There are patients who
have stayed in the ICU for three or four weeks. With
this deadline of one week and then rolling their eyes,
saying: ‘Oh, 10 days already!’ For us, this is nonsense;
it’s no reason to turn down an organ. (IP 05)
Lab results. The majority of interviewed surgeons
reported to routinely check the laboratory values of
the donor, but none named concrete limits. The
donor’s lab results are only one of many aspects thatinfluence the accept/refuse decision. Some surgeons
stated that lab results play a minor role compared to
the organ macroscopy.
Interdependence of donor characteristics. Most
surgeons explained that as a rule, none of the
mentioned donor criteria alone justified an organ
refusal; different factors need to be weighed against
each other. Organs may be declined for a number of
relative risk factors. It became clear, throughout the
interviews, that different factors were not assessed in
relation to each other in a systematic process, but
very individually and intuitively for every donor.
The decision is cumulative: old age, pancreatitis, poor
circulation, and then - on top of that - maybe
overweight. Then you add it all up. But refusing it [the
organ] just because of a single criterion, we wouldn’t
do that. (IP 05)
The refusal reasons that are given to the ET, these are
just an accumulation of bad gut feelings. (IP08)
P-PASS: The P-PASS, a score system combining
several risk factors of the donor, does not serve as a
decision aid; four out of 14 interview partners
mentioned that they use it, but explained that its
significance was either limited or decreasing in
importance.
Matching between donor and potential recipient. The
majority of interview partners stated that it is not
crucial that the donated organ matches well with the
potential recipient, e.g. in terms of size – other than
e.g. in liver transplantation.
Evidence base. Although not explicitly asked in the
interview, the surgeons expressed that their criteria
and cut-offs are based on various grounds, as
presented in Table 2.
2. Organ macroscopy
The surgeons stated unanimously that the macroscopy
of the pancreas is the key parameter for judging its
quality. Many surgeons described it as superior to
information about the donor’s general medical
condition for the assessment of the pancreas quality.
If the CRP is a little high, it doesn’t mean that you
can’t transplant [the pancreas]. It’s the same with
lipase: as long as it isn’t above 1000 [U/l], it doesn’t
bother me. If it [the pancreas] is macroscopically fine
and recovered well, you would certainly transplant it.
(IP 09)
Table 2 Basis of the assessment of medical donor
characteristics
On which basis do transplant surgeons assess medical donor
characteristics?
Category Frequency* Sample quote
1) International
literature
3/14 With the pancreas, I actually stick to the
published data from Minneapolis, that is
to Sutherland [et al.], on risk factors for
organ loss…to this study with more than
1,000 pancreas transplantations. (IP 02)
2) Hospital
guidelines
2/14 We have relatively strict guidelines…It
starts already with age. As a rule, we do
not accept organs that are more than
40 years old. Institutional guidelines.
(IP 06)
3) Peer custom 2/14 There’s this age limit‚ 50 years‘. Wherever
that may come from. (IP 12)
[I check] donor age, cause of death,…
weight. These are the essential [factors]. I
guess this is generally valid, everywhere.
We don’t have special [age] regulations [in
our center]. (IP 08)
4) Personal
clinical
experience
4/14 When I look back on our most recent
pancreases, they were all between 45 and
55 years [old]. …I think we can do it,
transplanting these organs, because we
don’t have these long shipping times [like
in the USA],… we are very successful at it.
(IP 05)
Polytrauma… whoever refuses that per se,
but accepts a 40- or 50-year-old, who has
seen younger days – my personal opinion
is that this is wrong. (IP 11)
*The numbers do not add up to 14, because not every interview supplied
sufficient information to allow for a clear categorization. In addition, 2
interviewees were coded for 2 categories, because they relied on the scientific
literature, but also considered their clinical experience.
Table 3 Handling the pancreas assessment of the recovery team
If the recovery team describes the pancreas quality as being poor, transp
Category Frequency* Sample
1) The interviewee adopts the assessment of the
recovery team
3/14 If [the d
then it i
2) The interviewee adopts the assessment only
if he knows and trusts the recovery surgeon
3/14 There’s a
never se
these or
know th
what he
[the don
transpla
assessm
you can
3) The interviewee does not rely on the assessment
of the recovery team. He prefers to accept the
organ in (almost) any case and assess it personally
6/14 [Assessm
people w
rule I co
somethi
persona
organ is
*The numbers do not add up to 14, because not every interview supplied sufficient in
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but the nephrologists primarily look at age, lab results,
sodium, amylase, … creatinine, glucose (…). I rather
look at the parenchyma (…), vascularization [and the]
cold ischemic time. (IP 07)
3. Confidence in recovery team
Pancreas macroscopy as viewed by recovery team.
Normally, the transplant surgeons who need to
decide to accept an organ have to rely on the donor
surgeon’s judgment of the organ macroscopy, often
communicated via phone. If the recovery team
describes the pancreas quality as poor, transplant
surgeons react differently, according to the
interviews, as shown in Table 3. Trust plays an
important role in this context.
The policy of eagerly accepting offered pancreases
with the aim to inspect the organs personally
(Table 2, 2nd category) is explicitly criticized by one
interviewee. This approach might decrease the
organ’s probability to be transplanted elsewhere in
case of refusal, due to overlong cold ischemic time.
There are certainly centers that accept such an organ
just so that they can have it and, more or less, take it
off the market for any other center. And then in the
end, [they] decide not to transplant it. And eventually,
with this approach, you won’t be able to transplant it
at all. You experience that every day basically. This is
definitely the wrong trend and you have to work
against it. And if you …start that too,…in order not to
fall behind, then this spiral will keep on going. It’s the
same as in the 1980s with the arms race between the
USA und Soviet Union …“. (IP02)lant surgeons react differently:
quote
onor surgeon] says: ‘It’s obviously hardened’, then you needn’t discuss it,
s hardened. (IP 09)
matter of trust involved here. […] We know that people who have
en (or) performed pancreas transplantations in their lives are recovering
gans. I think that’s difficult… the foundation of trust is missing there. If I
at this and that person has recovered the organ, [and that] he knows
is doing, then I can …say l’ll take it. (IP 14) When I am informed that
or surgeon] is working with a center that has never had a pancreas
nt program, then, honestly speaking, I’m very sceptical… A macroscopic
ent from somebody who isn’t even familiar with it [pancreas transplant],
completely forget that. (IP 08)
ent of the donor surgeon] - I know, from experience, that there are
ho have no idea whatsoever what a pancreas should look like. So as a
nsider [their assessment] for my decision, [but] unless there’s an injury or
ng that clearly precludes [a transplantation], … I’d rather look at it
lly. (IP 12) [We accept] even if the recovery team informs us that the
fatty or hard – if the parameters on paper are okay. (IP 05)
formation to allow for clear categorization.
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interviewed consultants agreed that the success of
the transplantation is dependent upon a skilled
organ recovery. In principal, this factor cannot
influence the accept/refuse decision prior to actually
receiving the accepted organ in the transplant
center; however, there were hints that a lack of
confidence in the donor surgeon’s competence
might influence the decision to accept an organ.
For me, it’s essential to have a good donor and an
excellent recovery. That‘s why I‘m convinced […] that
you can say that your reason for refusal was that the
recovery surgeon had no clue. And I‘m one of the few
people who gives this as the reason. (IP04)
4. Capacity of transplant center
The vast majority of the interviewed transplant
surgeons was convinced that transplant centers in
Germany occasionally turn down pancreas offers
due to staff shortage. However, nine out of 14 clearly
ruled out that option for their own respective
hospitals, declaring that refusals on the grounds of
staff shortage were ‘nonsense’ or ‘a non-issue’.
According to the interview partners, the main
reason for capacity problems is a limited number of
experienced transplant surgeons in a hospital,
coinciding with sickness, holidays or scientific
conferences. Three interviewed surgeons admitted
that they had already refused organs for capacity
reasons.
I’m with a center now where this [capacity] problem is
not really the issue. Because we’ve spread ourselves out
pretty well…So there’s always someone there who is
available and who is able to transplant a pancreas. I
could certainly imagine though, that it’s different in
smaller centers, because I already know how difficult it
is for us to organize ourselves this way. (IP 11)
I have already refused organs because it simply wasn’t
possible, logistically. On Easter Sunday, an organ offer
arrives, and the surgeon on call is sick. Then I have to
refuse the organ for organizational reasons. (IP 07)
We inform all potential recipients on the waiting list
about the possibility of a capacity shortage – for
whatever reasons: ICU bed, surgeon, other things… I
have already cancelled organs due to capacity
problems. We communicate this to our patients in a
transparent way. (IP 08)
Whereas two interview partners emphasized that it
was the obligation of a transplant center to have the
necessary resources for transplantation available atany time and under any circumstances, others (6/14)
described capacity problems as unavoidable or even
legitimate.
If you provide a transplant program in your hospital,
you have to make sure that the organs that come in
can be transplanted. […] You also have the
responsibility for the patient, who has been on the
waiting list for years. And then say, ‘Oh, there were three
others in parallel and there was only one surgeon who
had to take care of all of them” – the patient on the
waiting list will not understand that.’ (IP05)
[A transplant surgeon] is allowed to get sick, to go on
holiday…, meaning that he can‘t [operate]. And I can
very well imagine that someone says, due to logistical
reasons [they can‘t do it]. And this shouldn‘t be seen
as a reason to stigmatize these people. (IP04)
It transpired in the interviews that transplant
surgeons might be led into using medical reasons as
a pretext when an organ needs to be refused for
organizational reasons.
5. Previous turn-downs by other centers
If the pancreas had previously been offered to other
transplant centers by Eurotransplant and had been
refused, it was of little to no relevance for most
interview partners.
We always look at the organ individually. You can’t
imagine what we have experienced – pancreases are
refused for the most diverse reasons. We always want
to see for ourselves what’s there. (IP 12)
In four out of 14 interviewed surgeons, however,
there was a tendency to consider or to at least be
influenced by the decisions of other transplant
centers.
I ask what was the reason [for turning down the
organ]. This is for me, above all, a time-saving factor.
When I get a phone call at 3 a.m., and they tell me
there had already been 3 centers. And these 3 centers
are certainly not that stupid, they must have had
some reason. (IP 08)
As a rule, a good organ is accepted by the first center.
If it isn’t accepted, this is already sort of suspicious.
(IP 07)
6. Patient’s prognosis
The interviewed surgeons pointed out that a
pancreas transplant differs from a liver, heart or lung
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vital. Therefore, the organ needs to be selected more
carefully, because the willingness to compromise is
smaller than in cases of life-threatening conditions.
This may lead to a cautious acceptance policy.
If I am in doubt, I’d rather refuse. Simply because the
recipients are so selected. You can hardly expect them to
put up with the possibility that it doesn’t work well
afterwards […] If you don’t transplant the recipient, the
chance that he or she dies is small. If you give him or
her a bad organ, the chance that he or she dies is
actually given. You simply have to consider that. (IP 08).
The waiting time …for pancreas-kidney-transplants in
Germany is… not so extreme that you need to rush
someone into transplant surgery…I cannot endanger a
human being in order to perform a transplant when I
know that an organ from a good pool will arrive
within the next 18 months anyway. (IP 13)
This flexibility in accepting or turning down an
offered pancreas is accentuated by the lack of clear
standards and cut-offs; therefore almost any
pancreas can be refused.
And most of the donors do have some flaw…. And
then this one flaw can be made into a big deal, and
that’s why we only utilize only [so few] of the offered
organs. And then there is the question: how many
flaws do you want to accept? If you don’t want to run
any risks, then you don’t accept any flaw. (IP 03)
7 Strategic aspects
Some further factors which relate to expectations of
the hospital administration or aspects of
competition (with other transplant centers) might
also influence the decision making process, although
this was only hinted at in few interviews.
Here, we need to justify ourselves very well, in the
clinic and to our boss, and need to have good reasons
if we turn down such an offer. (IP 05)
In addition, younger surgeons who are
inexperienced or surgeons from a center with a
higher rate of complications might decline an organ
offer in order not to risk a surgical failure, as two
interviewees surmised.
A lot of this is about experience. A center that, for
example, has had many complications will certainly
be more restrictive. And when there’s a tiny little thing
[about the pancreas], they say, for safety reasons, thatthey refuse it. A center with more experience and
fewer complications will surely loosen its criteria…
Experience plays a major role there. (IP 09)
Discussion
Principal findings
From the interview results we could gain insight into the
decision-making process of transplant surgeons who are
offered a pancreas: The main factors that influence the
decision (e.g. pancreas macroscopy, donor medical his-
tory) are relatively consistent throughout the interviews.
However, when analyzed in depth, there are extreme dif-
ferences between the surgeons’ assessment and general
handling of pancreas offers. Firstly, while nearly all of
interviewed surgeons list the same medical donor factors
as being relevant for pancreas selection (above all donor
age, time of ICU stay, and lab results), the assessment of
these factors varies substantially between the surgeons;
no standardized or consistent cut offs exist. For example,
some surgeons told the interviewer that they had no
doubts about accepting the pancreas of a 55-year old if
the other parameters were favorable, whereas others
claimed not to accept the pancreas of a donor over 40.
Secondly, the macroscopic appearance of the donor
organ and the technical quality of the pancreas recovery
are the predominant factors which influence the deci-
sion. In Germany, the transplanting surgeons usually do
not perform the pancreas recovery as well, so the macro-
scopy is described to them on the telephone. The trans-
plant surgeons differed significantly as to whether or not
they relied on the donor surgeon’s assessment of the
macroscopic pancreas quality. Some prefer to have the
organ shipped to their center even if it has been de-
scribed as having poor quality. Others trust the donor
surgeon’s judgment – some surgeons do so in every case
and others only if they know and have confidence in the
respective donor surgeon.
Non-medical factors play a minor role, but certainly
exist; above all, capacity problems can lead to the refusal
of pancreases in some centers. Interestingly, the sample
was split on the legitimacy of occasional staff shortages.
It became clear in the interviews that the relatively be-
nign prognosis of the patients on the pancreas waiting
list may induce surgeons to wait for excellent (‘flawless’)
organs. This restrictive policy is in contrast to some sur-
geons’ preference to accept pancreases in a very permis-
sive way – even if turned down frequently before and
having been described as macroscopically poor – so that
they can inspect and evaluate the organ personally.
Strengths and weaknesses of study
Although the phenomenon of pancreas under-utilization
is well known in European and North American trans-
plantation networks and has been described as a ‘major
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the underlying reasons has been only superficial thus far.
The strength of this study lies in the investigation of one
of the pivotal steps in the allocation process: the trans-
plant surgeon’s decision to use or not to use an offered
pancreas. The main limitation of the study is that the
interview partners were recruited by purposive sampling,
and were limited to a number of 14 interview partners.
Consequently, it cannot be assumed that the findings
presented here are representative of the views of all pan-
creas transplant surgeons in Germany. However, the aim
of qualitative studies is not to receive representative
data, but to gain a deeper understanding of social and
psychological processes. Using a qualitative study design
allowed us to tap personal attitudes and experiences
that are not readily expressed in response to survey
questions [16], and that are key to understand the com-
plex processes and conditions involved in making the
decision. While the number of interviewed transplant-
ation surgeons was relatively small, the selected inter-
view partners represented all German transplantation
centers that perform five or more pancreas transplanta-
tions per year, thus constituting a very balanced and
almost representative sample. The use of the same inter-
viewer for all participants, and two independent re-
searchers for data analysis ensured quality control and
minimal interpretive bias.
Comparison with other studies
In order to explain the phenomenon of pancreas under-
utilization, few quantitative studies analyzed donor char-
acteristics of transplanted and/or discarded pancreases.
Wullstein et al. compared donor profiles of accepted pan-
creas grafts versus grafts declined due to ‘medical reasons’.
They found significant differences between both groups
for cause of death, age, BMI, serum Lipase, alcohol abuse
and history of smoking. They concluded that these aspects
might be the most important reasons to refuse a pancreas
[17]. These medical characteristics are largely overlapping
with those named by the interviewed surgeons, although
Wullstein et al. had not included the length of ICU stay in
their analysis, which was a predominant aspect in the in-
terviews. However, our analysis shows that the reasons to
accept or refuse an offered pancreas cannot be pinpointed
to single donor characteristics, but are far more complex.
Wiseman et al. [18] analyzed multiple characteristics of
donors whose pancreas was used, and compared them to
donors whose pancreas was not used. This study found
that a significant number of potentially suitable donor
pancreases were not used, although no medical character-
istics that precluded transplantation were identified. In the
article’s discussion, Wiseman et al. speculated that ‘trans-
plant centers … may be reluctant to accept pancreases
that are not assessed by members of their own team or bycolleagues who have demonstrated experience in pancreas
transplantation.’ This notion by Wiseman, which was not
backed by any other data yet, could clearly be confirmed
by our study. Wiseman et al. also hypothesized that due to
the relatively short waiting time, ‘the tendency for pan-
creas programs to decline use of a pancreas …with the
hopes that an even more “optimal” donor could be forth-
coming in the near future may limit pancreas utilization’.
The finding of the interviews that some hospitals or sur-
geons display a stringent acceptance policy is consistent
with this supposition.
Meaning of the study/policy implications
The interviews shed light on some aspects that help ex-
plain the under-utilization of donor pancreases.
It became clear that transplant surgeons who decide to
accept or refuse a pancreas offer always act on conflict-
ing priorities: on one hand, the expectations of patients
and hospital administration not to turn down a rare and
precious donor organ; and on the other hand, the fear of
endangering the patient’s health by accepting an organ
that is not flawless. The latter is especially important in
pancreas transplantation because unlike liver or heart
transplantation, the patient’s condition is usually not life
threatening, so there is less willingness to compromise.
If many centers dictate a cautious acceptance policy, or-
gans might be refused repeatedly. Consequently a ‘cas-
cade effect’ [19] can ensue, because the refusal of one
center might - consciously or unconsciously - increase
the probability of further refusals, as the interview ana-
lysis suggests. This is especially critical if the allocation
process is still ongoing when the organ has already been
recovered. As a consequence, the extended ischaemic time
may result in an increase of discarded organs; it can also
lead to unequal access to donated pancreases [20]. Con-
versely, a very permissive acceptance policy that some
interview partners displayed might also lower the pancreas
utilization rate, because there is the risk involved that the
organ cannot be placed anymore if its macroscopy is not
considered favorable when the transplant surgeon inspects
the organ personally in his center.
The interview results suggested that the assessment of
medical donor characteristics is subjective, inconsistent
and hardly standardized. This observation can also be ex-
plained by the fact that the interviewed surgeons base
their cut-offs on varying evidence or customs. A more
standardized approach in terms of cut-offs seems to be
difficult, however, because one parameter needs to be
assessed in conjunction with other risk factors. One has to
discuss whether the allocation process would profit from a
better standardization or an evidence-based approach.
Particularly younger surgeons who have less experience
might benefit from recommendations or guidelines, which
can be developed by experts. However, one needs to
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or not a pancreas is suitable for transplantation, as re-
cently pointed out by Magione et al. [21].
Within the relatively small community of surgeons
who are experienced in pancreas transplantation, donor
surgery and pancreas surgery, the aspect of trust seems
to be an influential factor in the decision-making
process: confidence in the donor surgeon and his or her
capacity to a) assess the pancreas quality and b) to re-
cover a pancreas without damaging it, and maybe even
trust in the transplant center that had turned down the
organ offer prior to one’s own decision. Better and more
standardized training or perhaps more rigorous selec-
tion of donor surgeons could improve the expertise and
thus boost confidence.
Conclusion
The assessment of medical donor characteristics is highly
subjective and inconsistent. Both very cautious as well as
very permissive acceptance policies may render the alloca-
tion process less efficient. A more standardized policy
should be discussed. Finally, better training for donor sur-
geons seems advisable, in order to increase trust and thus
pancreas utilization.
Endnote
aP-PASS = pre-procurement pancreas allocation suit-
ability score, combining nine donor parameters, e.g. age,
body mass index, ICU stay, and (nor)adrenaline use. The
DRI (donor risk index), an alternative prognostic score
for pancreas transplantation, is not commonly used in
Germany and was therefore not included explicitly in
the interview guide.
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